← Leaderboards
C Robert Horsburgh
Boston Medical Center
$21,596,833
Attributed
$29,298,576
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,069,988 · 12
CDC$3,228,588 · 2
By mechanism
U01$12,378,603 · 2
R01$7,629,767 · 3
U48$3,228,588 · 2
U19$2,872,910 · 2
T32$2,862,335 · 1
R34$281,016 · 1
Top collaborators
- David Alland13 shared
- Padmini Salgame13 shared
- Payam Nahid7 shared
- Timothy R Sterling5 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsTuberculosis TreatmentTuberculosisMultidrug-Resistant TuberculosisPersonsMycobacterium TuberculosisRelapseProspectiveBiological MarkersTreatment OutcomeClinical TrialsReportingResistanceEnrollmentRegimenPreventTreatment ProtocolsMycobacterialCohortOrganismHigh RiskNational Institute Of Allergy And Infectious DiseaseSputumResearch Design
Grant awards (60)
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$1,157,460
U01 · FY2025 · AI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$184,085
U01 · FY2025 · AI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$92,645
U01 · FY2025 · AI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$1,350,629
U01 · FY2023 · AI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$1,342,487
U01 · FY2022 · AI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$1,357,160
U01 · FY2021 · AI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$905,202
R01 · FY2021 · AI · contact PI
DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial$1,470,699
U01 · FY2020 · AI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$929,089
R01 · FY2020 · AI · contact PI
Clinical Core$618,699
U19 · FY2020 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$884,552
R01 · FY2019 · AI · contact PI
Clinical Core$202,101
U19 · FY2019 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$900,696
R01 · FY2018 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$106,673
U19 · FY2018 · AI · contact PI
Clinical Core$24,317
U19 · FY2018 · AI · contact PI
Clinical Core$15,491
U19 · FY2018 · AI · contact PI
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)$998,235
R01 · FY2017 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$347,049
T32 · FY2017 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$216,253
U19 · FY2017 · AI · contact PI
Clinical Core$44,147
U19 · FY2017 · AI · contact PI
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment$1,229,745
U01 · FY2016 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$255,998
U19 · FY2016 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$172,120
T32 · FY2016 · AI · contact PI
Clinical Core$74,224
U19 · FY2016 · AI · contact PI
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment$1,314,777
U01 · FY2015 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$757,912
U19 · FY2015 · AI · contact PI
Clinical Core$27,211
U19 · FY2015 · AI · contact PI
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment$1,342,713
U01 · FY2014 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$435,831
U19 · FY2014 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$289,500
T32 · FY2014 · AI · contact PI
Clinical Core$94,053
U19 · FY2014 · AI · contact PI
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment$1,536,203
U01 · FY2013 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$459,808
T32 · FY2013 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$387,397
T32 · FY2012 · AI · contact PI
BU Clinical HIV/AIDS Research Training Program$82,774
T32 · FY2011 · AI · contact PI
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment$281,016
R34 · FY2010 · AI · contact PI
PARTNERS IN HEALTH AND HOUSING PREVENTION RESEARCH CENTER$790,000
U48 · FY2009 · DP · contact PI
Natural History of Hepatitis C Infection in HIV Disease$866,282
R01 · FY2008 · DA · contact PI
Partners in Health and Housing Prevention Research Cent*$725,000
U48 · FY2008 · DP · contact PI
Partners in Health and Housing Prevention Research Cent*$725,000
U48 · FY2007 · DP · contact PI
BU Clinical HIV/AIDS Research Training Program$151,190
T32 · FY2007 · AI · contact PI
Partners in Health and Housing Prevention Research Cent*$3,589
U48 · FY2007 · DP · contact PI
Partners in Health and Housing Prevention Research Cent*$984,999
U48 · FY2006 · DP · contact PI
BU Clinical HIV/AIDS Research Training Program$272,175
T32 · FY2006 · AI · contact PI
Natural History of Hepatitis C Infection in HIV Disease$59,266
R01 · FY2006 · DA · contact PI
Natural History of Hepatitis C Infection in HIV Disease$861,647
R01 · FY2005 · DA
BU Clinical HIV/AIDS Research Training Program$353,257
T32 · FY2005 · AI
ENDOTHELIAL DYSFUNCTION STUDY$7,500
M01 · FY2005 · RR
OSTEOPOROSIS AND NUTRITIONAL EVALUATION STUDY$1,665
M01 · FY2005 · RR
Partners in Health and Housing Prevention Research Cent*$0
U48 · FY2005 · DP
Partners in Health and Housing Prevention Research Cent*$0
U48 · FY2005 · DP
BU Clinical HIV/AIDS Research Training Program$210,701
T32 · FY2004 · AI
Endothelial Dysfunction Study$34,383
M01 · FY2004 · RR
Hepatitis C Infection in HIV Individuals and Controls$1,809
M01 · FY2004 · RR
Partners in Health and Housing Prevention Research Cent*$0
U48 · FY2004 · DP
NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE$542,549
R01 · FY2003 · DK
BU Clinical HIV/AIDS Research Training Program$136,364
T32 · FY2003 · AI
NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE$75,638
R01 · FY2003 · DK
NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE$532,896
R01 · FY2002 · DK
NATURAL HISTORY OF HEPATITIS C INFECTION IN HIV DISEASE$73,715
R01 · FY2002 · DK